Core Viewpoint - GLP-1 drugs, initially approved for type 2 diabetes treatment, have shown significant weight loss and health improvement effects, but their efficacy relies heavily on patient cooperation in dietary and lifestyle changes [2][18]. Group 1: Importance of Dietary Management - Dietary management is crucial for two main reasons: it alleviates common side effects like nausea and constipation, and ensures that the reduced food intake remains nutritionally dense [3][6]. - A registered dietitian emphasizes that patients should aim to reduce their usual food intake by half while maintaining high nutritional value [3][5]. Group 2: Key Dietary Recommendations - **Prioritize Protein Intake**: Recommended daily protein intake is about 1.2 grams per kilogram of body weight, with sources including eggs, fish, poultry, Greek yogurt, and legumes [6]. - **Increase Dietary Fiber**: Fiber is essential for gut health and preventing constipation, with recommendations to consume whole grains, legumes, leafy greens, oats, and berries [8]. - **Stay Hydrated**: Adequate water intake helps alleviate nausea and constipation, with a suggestion of 8 to 10 cups of water or unsweetened beverages daily [9]. - **Frequent Small Meals**: Eating smaller, more frequent meals can prevent overeating and manage symptoms like bloating and nausea [11][12]. - **Chew Slowly**: Eating slowly helps recognize satiety signals, reducing the risk of overeating [13]. - **Avoid Unhealthy Foods**: Reducing intake of greasy, processed foods and alcohol is advised to maintain stable blood sugar levels and avoid gastrointestinal discomfort [15]. - **Moderate Exercise**: Regular physical activity aids digestion and overall metabolism, which is particularly beneficial for GLP-1 users [17]. Group 3: When to Seek Medical Help - Patients experiencing severe nausea, frequent vomiting, or a significant lack of appetite should consult a doctor to adjust medication dosages [17].

整理 | GLP1减重宝典内容团队 在制药行业，一项始终困扰投资者与业内人士的问题是：**如果两家公司获得同一个分子，它们的成果是否一致？**答案显然是否定的。关键 不在于起点的相似，而在于各企业如何将技术、产品线和市场能力整合为真正的临床与商业价值。 正是基于这个洞察，咨询公司 IDEA 发布了一份引人注目的指数，尝试用"创新（Innovation）"和"发明（Invention）"两个维度，系统性地评 估全球顶尖制药企业的价值创造能力。"发明"强调将新技术或概念以独特方式结合，创造前所未有的成果；"创新"则是衡量企业如何将这些发 明转化为有意义的市场回报。 这份指数评估了截至2025年1月1日全球市值排名前30的生物医药公司，并绘制出两份榜单：创新十强与发明十强。 | | | | | | INNOVATION ↓ | INVENTION | | --- | --- | --- | --- | --- | --- | --- | | Eli Lilly | ↑ 3 | | | | 1 | 6 | | Merck & Co | | ↑ 8 | | | 2 | 7 | | AstraZeneca | | ↑ 4 ...

整理 | GLP1减重宝典内容团队 前美国食品药品监督管理局局长、新冠疫情期间"曲速行动"的主要策划人之一大卫·凯斯勒，对现代医学中最隐蔽的威胁之一——内脏脂 肪——发出了警告。这种被称为"毒腰"的深层腹部脂肪环绕着重要器官，与高血压、2型糖尿病、心血管疾病、某些癌症甚至痴呆症等慢 性疾病密切相关。 ▍ 它们能改变一个国家的健康轨迹吗？ 尽管存在这些缺点，凯斯勒相信，如果在医生的监督下合理使用，GLP-1 药物可以彻底改变慢性病的管理。内脏脂肪不仅仅是美容；它 具有代谢活性，分泌脂肪酸和炎症化学物质，干扰胰岛素功能并升高血糖水平。从1999年到2018年，美国高胰岛素血症的患病率从28% 上升到41%以上。 凯斯勒表示："它是慢性疾病的罪魁祸首。"他认为，减少这类脂肪可以显著改善公众健康状况，并大幅削减国家医疗成本。"心脏病专 家、肾脏专家、肿瘤学家——他们才刚刚意识到这一发现。" 凯斯勒的担忧并非出于学术层面。 在与体重斗争了一辈子之后，他转向了新型GLP-1药物——例如Wegovy和Ozempic——这些药物正 在改变肥胖治疗的格局。 在他的新书《饮食、药物和多巴胺》中，他详细描述了自己的个人历程，成功减 ...

胡带带 国家官方减肥指南正式 上线 遵循"管住嘴迈开腿"原则 我国它有通过审批的减肥药物 可采取合理科学方式进行体重管理 THREE - YEAR ACTION ON WEIGHT MANAGEMENT 商务合作/业务需求/加入专家库 扫码添加主理人助理 备注 「姓名+行业+公司职务+需求」 体重量家卫生健康委员会 National Wealth Commission of the People's Republic of China 过度节食减肥真的靠谱吗？ 从医学角度看，营养治疗是肥胖管理的基础，包括限能量饮食、高蛋白饮食、轻断食和低碳水化合物饮食等方 式。轻断食是其中的一种选择。专家提醒，轻断食并不等于完全不吃饭，过度节食并不科学。 北京友谊医院减重与代谢外科主任张鹏指出， 科学的节食应保证每天摄入充足的蛋白质、不饱和脂肪酸、微量元素、维生素和水分，在此基础上合理控制总热量摄入。 "管住嘴"不等于"闭嘴不吃"！ 不吃晚餐未必能瘦 专家强调，不吃晚餐其实无法有效减肥。长期不吃晚餐，人体会将早餐和午餐摄入的热量优 先转化为脂肪，反而容易增重。一旦恢复晚餐，体重很可能迅速反弹。 断碳水减肥法是不是就是不吃主食 ...

整理 | GLP1减重宝典内容团队 对于任何尝试过减肥的人来说，这个故事可能听起来很熟悉：男性减少碳水化合物摄入，减重10磅，而女性按照同样的方法只能减重2 磅。长期以来，研究表明，总体而言，男性对节食和运动的反应往往比女性更快。 正因如此，最近的临床试验结果才引起了人们的关注，甚至有些令人惊讶。 注射型GLP-1药物（一种用于减肥的药物）对女性的平均效 果似乎优于男性。 造成这种差异的原因尚不清楚，但专家表示，了解其中涉及的生物学和行为因素至关重要，这样医生才能更有效地制定治疗方案。 点击关注，追踪最新GLP-1资讯 最近一项记录这一趋势的研究在欧洲肥胖大会上发表，并发表在《新英格兰医学杂志》上。这是两种GLP-1药物的首次直接比较：司美 格鲁肽（商品名Wegovy）和替尔泊肽（商品名Zepbound）。大约750名肥胖患者被分成两组，分别接受最高耐受剂量的Wegovy或 Zepbound治疗。 Zepbound是一种较新的药物，作用于两种影响饥饿感和血糖的肠道激素，而Wegovy仅针对其中一种。鉴于此，许多临床医生预计 Zepbound在减肥方面会优于Wegovy——事实也的确如此。平均而言，服用Zepb ...

整理 | GLP1减重宝典内容团队 罗氏公司于2025年5月11日在ClinicalTrials网站注册了一项名为GYMINDA的II期临床试验，旨在评估RO7204239联合替尔泊肽（tirzepatide） 在肥胖或超重且伴有至少一种体重相关并发症的非糖尿病成人中的疗效、安全性和耐受性。 RO7204239（又称GYM329）是一种由罗氏与中外制药共同开发的肌肉生长抑制素（myostatin，GDF8）单克隆抗体。该药物通过靶向清除血 浆和组织中的潜在性肌抑素（latent myostatin），阻断其被激活为抑制肌肉生长的活性形式，从而有望促进肌肉生长和改善肌肉萎缩相关疾 病。目前，RO7204239正在针对面肩肱型肌营养不良症（FSHD）和脊髓性肌萎缩症（SMA）等疾病开展临床研究。 为期24周的治疗后随访期。 该研究计划招募234名参与者，预计于2025年5月开始，2026年10月初步完成。 替尔泊肽是一种由礼来公司开发的双重GIP和GLP-1受体激动剂，已被批准用于治疗2型糖尿病和肥胖症。在一项为期72周的III期临床试验中， 替尔泊肽每周一次的注射治疗显示出显著和持续的体重减轻效果，平均体重减少 ...

Core Viewpoint - The National Health Commission of China has initiated a three-year "Weight Management Year" campaign to address the rising obesity rates and associated health risks, emphasizing the importance of weight management for national health and well-being [6][8]. Group 1: Reasons for National Focus on Weight Management - The obesity rate in China is projected to reach 70.5% among adults and 31.8% among children by 2030 if not effectively addressed, indicating a significant public health challenge [8]. - Obesity is linked to over 200 diseases, including type 2 diabetes, hypertension, and various cancers, highlighting the urgency of the obesity crisis [8]. Group 2: Common Misconceptions about Weight Loss - Many individuals mistakenly believe that extreme dieting or excessive exercise is the best way to lose weight, which can lead to counterproductive results [9]. - Overly restrictive diets, such as skipping meals or eliminating carbohydrates, can harm health and lead to weight rebound once normal eating resumes [9]. Group 3: Scientific Approaches to Weight Loss - A balanced diet is essential, with recommendations for a caloric distribution of 3:4:3 for meals, emphasizing whole grains, vegetables, and lean proteins [10]. - Regular physical activity is crucial, with guidelines suggesting at least 150 minutes of moderate-intensity exercise per week [11]. - Adequate sleep of 7-8 hours per night is necessary to prevent metabolic disruptions that can contribute to obesity [12]. Group 4: Medical Interventions for Weight Management - For individuals struggling to lose weight despite lifestyle changes, seeking professional medical help is advised, as obesity is a complex condition influenced by various factors [13]. - New medications, such as the GLP-1 receptor agonist, have shown promising results in weight loss and metabolic health improvement, with clinical studies indicating significant weight reduction [14].

整理 | GLP1减重宝典内容团队 5月16号，信达生物宣布： 胰高血糖素（GCG）/胰高血糖素样肽-1（GLP-1）双受体激动剂玛仕度肽在中国超重或肥胖合并代谢相关脂肪性肝 病（MAFLD）的受试者中的一项III期临床研究（GLORY-3）完成首例受试者给药 。 *本文仅供医疗卫生专业人士参考 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添加微信：andyxu365 加入专家库与我们深度讨论 本研究是一项在中国超重或肥胖合并MAFLD受试者中比较玛仕度肽与司美格鲁肽有效性和安全性的多中心、随机、开放标签的III期临床研究 （NCT06884293）。本研究计划入组约470例超重或肥胖（BMI≥27 kg/m 2 ）合并代谢功能障碍相关性脂肪性肝病（MAFLD）受试者，按1:1 的比例随机分配至玛仕度肽9 mg组或司美格鲁肽2.4 mg组。研究的主要终点是第48周时磁共振质子密度脂肪分数（MRI-PDFF）评估肝脏脂肪 含量 ...

Core Viewpoint - The article discusses the potential of GLP-1 agonists, such as Wegovy and Ozempic, not only for weight loss but also for altering brain functions and reducing cravings for various substances, which could have significant implications for addiction treatment [2][3]. Group 1: Impact on Cravings and Addictions - Users of Wegovy report reduced cravings not only for food but also for alcohol, cigarettes, shopping, and nail-biting, suggesting a broader impact on addictive behaviors [2]. - A study involving over 500,000 individuals with a history of opioid use disorder indicated that those taking Ozempic or similar GLP-1 drugs had a significantly lower likelihood of opioid overdose compared to those not using these medications [2]. Group 2: Mechanisms and Effects on Mental Health - GLP-1 agonists may reduce the motivation for food and addictive substances by targeting brain areas responsible for food reward signals, which is currently being tested for potential use in treating alcohol and drug addiction [3]. - Research shows that GLP-1 agonists are associated with lower rates of anxiety and depression, potentially due to weight loss and the reduction of "food noise," allowing individuals to enjoy other aspects of life [5]. - A trial involving 19 patients with severe depression or bipolar disorder indicated that liraglutide improved mood, attention, and cognitive function, regardless of weight loss [7]. Group 3: Ongoing Research and Side Effects - The mechanisms behind GLP-1's effects are still being studied, with researchers noting that understanding these mechanisms could help address significant health questions [8]. - Side effects of semaglutide include constipation, muscle wasting, and accelerated facial aging, which may arise from changes in fat tissue and stem cell growth [8]. - There is excitement about the potential broad applications of semaglutide, with ongoing discussions about its possible benefits for various conditions, including cancer and Alzheimer's disease, although more research is needed to validate these claims [10].

今年35岁的小正（化名）怎么也没想到，肥胖竟让他患上了阻塞性睡眠呼吸暂停综合征。每晚因呼吸不畅频繁惊醒，起夜多达七八次。年纪轻 轻，他已被高血压、糖尿病缠身。体重最高时接近380斤，"胖墩墩"的生活让小正身心俱疲。 肥胖症是一种由遗传、内分泌及环境等多重因素共同导致的慢性代谢性疾病。随着经济发展和生活水平的提升，我国居民的生活方式和饮食结 构发生了巨大变化，超重和肥胖已成为影响大众健康的重大公共卫生难题。 据《中国居民营养与慢性病状况报告（2020年）》显示，2018年我国成年人超重率和肥胖率分别达到34.3%和16.4%；6至17岁儿童青少年的超 重率和肥胖率分别为11.1%和7.9%，且呈逐年上升趋势。国家卫健委发布的《体重管理指导原则（2024年版）》也指出，若不加以控制，预计 到2030年，我国成人和儿童的超重肥胖率将分别高达70.5%和31.8%。 肥胖不仅影响外在形象，更是多种慢性疾病的"幕后推手"。体重异常，特别是超重和肥胖，是高血压、糖尿病、高血脂、心脑血管疾病及部分 癌症等多种慢性病的重要危险因素。肥胖还会导致医疗开支增加、工作效率下降、生活质量受损，并引发自卑、抑郁等心理问题。这些困扰因 ...